BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dolscheid-Pommerich R, Bartok E, Renn M, Kümmerer BM, Schulte B, Schmithausen RM, Stoffel-Wagner B, Streeck H, Saschenbrecker S, Steinhagen K, Hartmann G. Correlation between a quantitative anti-SARS-CoV-2 IgG ELISA and neutralization activity. J Med Virol 2022;94:388-92. [PMID: 34415572 DOI: 10.1002/jmv.27287] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 36.0] [Reference Citation Analysis]
Number Citing Articles
1 El-ghitany EM, Hashish MH, Farghaly AG, Omran EA. Determining the SARS-CoV-2 Anti-Spike Cutoff Level Denoting Neutralizing Activity Using Two Commercial Kits. Vaccines 2022;10:1952. [DOI: 10.3390/vaccines10111952] [Reference Citation Analysis]
2 Erber AC, Wagner A, Karachaliou M, Jeleff M, Kalafatis P, Kogevinas M, Pepłońska B, Santonja I, Schernhammer E, Stockinger H, Straif K, Wiedermann U, Waldhör T, Papantoniou K. The Association of Time of Day of ChAdOx1 nCoV-19 Vaccine Administration With SARS-CoV-2 Anti-Spike IgG Antibody Levels: An Exploratory Observational Study. J Biol Rhythms 2022. [DOI: 10.1177/07487304221132355] [Reference Citation Analysis]
3 Olmstead AD, Nikiforuk AM, Schwartz S, Márquez AC, Valadbeigy T, Flores E, Saran M, Goldfarb DM, Hayden A, Masud S, Russell SL, Prystajecky N, Jassem AN, Morshed M, Sekirov I. Characterizing Longitudinal Antibody Responses in Recovered Individuals Following COVID-19 Infection and Single-Dose Vaccination: A Prospective Cohort Study. Viruses 2022;14:2416. [DOI: 10.3390/v14112416] [Reference Citation Analysis]
4 Kim J, Chang E, Park SY, Lee DW, Kang CK, Choe PG, Kim NJ, Oh MD, Park WB, Lee KH, Im SA. Evaluation of Seropositivity After Standard Doses of Vaccination Against SARS-CoV-2 in Patients With Early Breast Cancer Receiving Adjuvant Treatment. Oncologist 2022:oyac196. [PMID: 36218350 DOI: 10.1093/oncolo/oyac196] [Reference Citation Analysis]
5 Banjongjit A, Phirom S, Phannajit J, Jantarabenjakul W, Paitoonpong L, Kittanamongkolchai W, Wattanatorn S, Prasithsirikul W, Eiam-Ong S, Avihingsanon Y, Hansasuta P, Vanichanan J, Townamchai N. Benefits of Switching Mycophenolic Acid to Sirolimus on Serological Response after a SARS-CoV-2 Booster Dose among Kidney Transplant Recipients: A Pilot Study. Vaccines (Basel) 2022;10:1685. [PMID: 36298550 DOI: 10.3390/vaccines10101685] [Reference Citation Analysis]
6 Cucchiari D, Egri N, Rodriguez-espinosa D, Montagud-marrahi E, Casals-urquiza J, Del Risco-zevallos J, Bodro M, Ventura-aguiar P, Cofan F, Cacho J, Molina-andujar A, Rovira J, Banon-maneus E, José Ramirez-bajo M, Pérez-olmos A, Garcia-pascual M, Pascal M, Vilella A, Trilla A, Palou E, Revuelta I, Juan M, Campistol JM, Oppenheimer F, Moreno A, Miró JM, Bayés B, Diekmann F. Humoral and Cellular Immune Responses After a 3-dose Course of mRNA-1273 COVID-19 Vaccine in Kidney Transplant Recipients: A Prospective Cohort Study. Transplantation Direct 2022;8:e1389. [DOI: 10.1097/txd.0000000000001389] [Reference Citation Analysis]
7 Grunau B, Prusinkiewicz M, Asamoah-Boaheng M, Golding L, Lavoie PM, Petric M, Levett PN, Haig S, Barakauskas V, Karim ME, Jassem AN, Drews SJ, Sediqi S, Goldfarb DM. Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals. Microbiol Spectr 2022;:e0131522. [PMID: 36121252 DOI: 10.1128/spectrum.01315-22] [Reference Citation Analysis]
8 Collins E, Galipeau Y, Arnold C, Bosveld C, Heiskanen A, Keeshan A, Nakka K, Shir-mohammadi K, St-denis-bissonnette F, Tamblyn L, Vranjkovic A, Wood LC, Booth R, Buchan CA, Crawley AM, Little J, Mcguinty M, Saginur R, Langlois M, Cooper CL. Cohort profile: S top the Spread Ottawa (SSO) a community-based prospective cohort study on antibody responses, antibody neutralisation efficiency and cellular immunity to SARS-CoV-2 infection and vaccination. BMJ Open 2022;12:e062187. [DOI: 10.1136/bmjopen-2022-062187] [Reference Citation Analysis]
9 Tukhvatulin AI, Gordeychuk IV, Dolzhikova IV, Dzharullaeva AS, Krasina ME, Bayurova EO, Grousova DM, Kovyrshina AV, Kondrashova AS, Avdoshina DV, Gulyaev SA, Gulyaeva TV, Moroz AV, Illarionova VV, Zorkov ID, Iliukhina AA, Shelkov AY, Botikov AG, Erokhova AS, Shcheblyakov DV, Esmagambetov IB, Zubkova OV, Tokarskaya EA, Savina DM, Vereveyko YR, Ungur AS, Naroditsky BS, Ishmukhametov AA, Logunov DY, Gintsburg AL. Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates. Emerging Microbes & Infections. [DOI: 10.1080/22221751.2022.2119169] [Reference Citation Analysis]
10 Hosseini SSJ, Dudakova A, Kummer K, Zschüntzsch J. SARS-CoV-2-Antikörper-Antwort auf die zweite COVID-19-Impfung bei neuromuskulären Patienten unter immunmodulierender Therapie. Nervenarzt 2022. [DOI: 10.1007/s00115-022-01363-6] [Reference Citation Analysis]
11 Omran EA, Habashy RE, Ezz Elarab LA, Hashish MH, El-barrawy MA, Abdelwahab IA, Fekry MM. Anti-Spike and Neutralizing Antibodies after Two Doses of COVID-19 Sinopharm/BIBP Vaccine. Vaccines 2022;10:1340. [DOI: 10.3390/vaccines10081340] [Reference Citation Analysis]
12 Madureira R, Ferreira SA, Marion MAL, Bettoni F, Ganem F, Camargo AA, Morinaga CV. Seroprevalence of SARS-CoV-2 in Emergency Department Healthcare Workers at Sírio-Libanês Hospital, Brazil. Health Secur 2022. [PMID: 35960271 DOI: 10.1089/hs.2022.0045] [Reference Citation Analysis]
13 Zecca E, Rizzi M, Tonello S, Matino E, Costanzo M, Rizzi E, Casciaro GF, Manfredi GF, Acquaviva A, Gagliardi I, Calzaducca E, Mallela VR, D'Onghia D, Minisini R, Bellan M, Castello LM, Gavelli F, Avanzi GC, Patrucco F, Chiocchetti A, Pirisi M, Rigamonti C, Lilleri D, Sola D, Sainaghi PP. Ongoing Mycophenolate Treatment Impairs Anti-SARS-CoV-2 Vaccination Response in Patients Affected by Chronic Inflammatory Autoimmune Diseases or Liver Transplantation Recipients: Results of the RIVALSA Prospective Cohort. Viruses 2022;14:1766. [PMID: 36016388 DOI: 10.3390/v14081766] [Reference Citation Analysis]
14 Frische A, Brooks PT, Gybel-brask M, Sækmose SG, Jensen BA, Mikkelsen S, Bruun MT, Boding L, Strandh CP, Jørgensen CS, Krogfelt KA, Fomsgaard A, Lassauniere R. Optimization and evaluation of a live virus SARS-CoV-2 neutralization assay. PLoS ONE 2022;17:e0272298. [DOI: 10.1371/journal.pone.0272298] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Bánki Z, Seekircher L, Falkensammer B, Bante D, Schäfer H, Harthaller T, Kimpel J, Willeit P, von Laer D, Borena W. Six-Month Follow-Up of Immune Responses after a Rapid Mass Vaccination against SARS-CoV-2 with BNT162b2 in the District of Schwaz/Austria. Viruses 2022;14:1642. [DOI: 10.3390/v14081642] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Kim J, Chang E, Park SY, Lee D, Kang CK, Choe PG, Kim NJ, Oh M, Park WB, Lee K, Im S. Evaluation of Seropositivity after Standard Doses of Vaccination against SARS-CoV-2 in Early Breast Cancer Patients Receiving Adjuvant Treatment.. [DOI: 10.1101/2022.07.23.22277888] [Reference Citation Analysis]
17 Suntronwong N, Assawakosri S, Kanokudom S, Yorsaeng R, Auphimai C, Thongmee T, Vichaiwattana P, Duangchinda T, Chantima W, Pakchotanon P, Chansaenroj J, Nilyanimit P, Srimuan D, Thatsanatorn T, Sudhinaraset N, Wanlapakorn N, Mongkolsapaya J, Poovorawan Y. Strong Correlations between the Binding Antibodies against Wild-Type and Neutralizing Antibodies against Omicron BA.1 and BA.2 Variants of SARS-CoV-2 in Individuals Following Booster (Third-Dose) Vaccination. Diagnostics (Basel) 2022;12:1781. [PMID: 35892491 DOI: 10.3390/diagnostics12081781] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Stumpf J, Schwöbel J, Karger C, Schirutschke H, Mauer R, Klimova A, Tonn T, Hugo C. Anti-SARS-CoV-2 Revaccination Success in Kidney Transplant Recipients With No Initial Humoral Response Is Linked to Primary Vaccine Type. Front Med 2022;9:910987. [DOI: 10.3389/fmed.2022.910987] [Reference Citation Analysis]
19 Thongkum W, Thongheang K, Tayapiwatana C. The Occluded Epitope Residing in Spike Receptor-Binding Motif Is Essential for Cross-Neutralization of SARS-CoV-2 Delta Variant. Curr Issues Mol Biol 2022;44:2842-55. [PMID: 35877419 DOI: 10.3390/cimb44070195] [Reference Citation Analysis]
20 Suntronwong N, Assawakosri S, Kanokudom S, Yorsaeng R, Auphimai C, Thongmee T, Vichaiwattana P, Duangchinda T, Chantima W, Pakchotanon P, Chansaenroj J, Nilyanimit P, Srimuan D, Thatsanatorn T, Sudhinaraset N, Wanlapakorn N, Mongkolsapaya J, Poovorawan Y. Strong correlations between the binding antibodies against wild type and neutralizing antibodies against omicron BA.1 and BA.2 variants of SARS-CoV-2 in individuals following booster (third dose) vaccination.. [DOI: 10.1101/2022.06.27.22276959] [Reference Citation Analysis]
21 Polvere I, Parrella A, Zerillo L, Voccola S, Cardinale G, D'Andrea S, Madera JR, Stilo R, Vito P, Zotti T. Humoral Immune Response Diversity to Different COVID-19 Vaccines: Implications for the "Green Pass" Policy. Front Immunol 2022;13:833085. [PMID: 35634315 DOI: 10.3389/fimmu.2022.833085] [Reference Citation Analysis]
22 Eyran T, Vaisman-Mentesh A, Taussig D, Dror Y, Aizik L, Kigel A, Rosenstein S, Bahar Y, Ini D, Tur-Kaspa R, Kournos T, Marcoviciu D, Dicker D, Wine Y. Longitudinal kinetics of RBD+ antibodies in COVID-19 recovered patients over 14 months. PLoS Pathog 2022;18:e1010569. [PMID: 35658051 DOI: 10.1371/journal.ppat.1010569] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Rotterdam J, Thiaucourt M, Weiss C, Schwaab J, Reiter A, Kreil S, Steiner L, Fenchel S, Popp HD, Hofmann WK, Bonatz K, Gerhards C, Neumaier M, Klein SA, Rao S, Jawhar M, Saussele S. Definition of factors associated with negative antibody response after COVID-19 vaccination in patients with hematological diseases. Ann Hematol 2022. [PMID: 35597847 DOI: 10.1007/s00277-022-04866-z] [Reference Citation Analysis]
24 Lange TM, Rotärmel M, Müller D, Mahone GS, Kopisch-Obuch F, Keunecke H, Schmitt AO. Non-linear transformation of enzyme-linked immunosorbent assay (ELISA) measurements allows usage of linear models for data analysis. Virol J 2022;19:85. [PMID: 35585588 DOI: 10.1186/s12985-022-01804-3] [Reference Citation Analysis]
25 Decarreaux D, Pouquet M, Souty C, Vilcu A, Prévot-monsacre P, Fourié T, Villarroel PMS, Priet S, Blanché H, Sebaoun J, Deleuze J, Turbelin C, Werner A, Kochert F, Grosgogeat B, Rabiega P, Laupie J, Abraham N, Guerrisi C, Noël H, Van der Werf S, Carrat F, Hanslik T, Charrel R, De Lamballerie X, Blanchon T, Falchi A. Seroprevalence of SARS-CoV-2 IgG Antibodies and Factors Associated with SARS-CoV-2 IgG Neutralizing Activity among Primary Health Care Workers 6 Months after Vaccination Rollout in France. Viruses 2022;14:957. [DOI: 10.3390/v14050957] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Seekircher L, Bánki Z, Kimpel J, Rössler A, Schäfer H, Falkensammer B, Bante D, Forer L, Schönherr S, Harthaller T, Sacher M, Ower C, Tschiderer L, Ulmer H, Krammer F, Laer DV, Borena W, Willeit P. Immune response to 2-dose BNT162b2 vaccination and risk of SARS-CoV-2 breakthrough infection: The Shieldvacc-2 study.. [DOI: 10.1101/2022.04.19.22273872] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
27 Tuells J, Parra-grande M, Santos-calle FJ, Montagud AC, Egoavil CM, García-rivera C, Caballero P, Gabaldón-bravo EM, Rodríguez-diaz JC, Hurtado-sánchez JA. Detection of Neutralizing Antibodies against SARS-CoV-2 Post-Vaccination in Health Care Workers of a Large Tertiary Hospital in Spain by Using a Rapid Test LFIC and sVNT-ELISA. Vaccines 2022;10:510. [DOI: 10.3390/vaccines10040510] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Infantino M, Manfredi M, Stacchini L, Cosma C, Grossi V, Lari B, Russo E, Amedei A, Benucci M, Veneziani F, Casprini P, Catalano CM, Cirrincione G, Bonaccorsi G, Pompetti A. The role of neutralizing antibodies by sVNT after two doses of BNT162b2 mRNA vaccine in a cohort of Italian healthcare workers. Clin Chem Lab Med 2022. [PMID: 35303766 DOI: 10.1515/cclm-2022-0170] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
29 Lai A, Caimi B, Franzetti M, Bergna A, Velleca R, Gatti A, Rossi PL, D’orso M, Pregliasco F, Balotta C, Calicchio G. Durability of Humoral Responses after the Second Dose of mRNA BNT162b2 Vaccine in Residents of a Long Term Care Facility. Vaccines 2022;10:446. [DOI: 10.3390/vaccines10030446] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
30 Grunau B, Golding L, Prusinkiewicz MA, Asamoah-boaheng M, Armour R, Marquez AC, Jassem AN, Barakauskas V, O’brien SF, Drews SJ, Haig S, Lavoie PM, Goldfarb DM, Medina RA, Dallmeier K. Comparative 6-Month Wild-Type and Delta-Variant Antibody Levels and Surrogate Neutralization for Adults Vaccinated with BNT162b2 versus mRNA-1273. Microbiol Spectr. [DOI: 10.1128/spectrum.02702-21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Salehi M, Hosseini H, Jamshidi HR, Jalili H, Tabarsi P, Mohraz M, Karimi H, Lotfinia M, Aalizadeh R, Mohammadi M, Ramazi S, Abdoli A. Assessment of BIV1-CovIran inactivated vaccine-elicited neutralizing antibody against the emerging SARS-CoV-2 variants of concern. Clinical Microbiology and Infection 2022. [DOI: 10.1016/j.cmi.2022.02.030] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
32 How J, Gallagher KME, Liu Y, Katsis K, Elder EL, Larson RC, Leick MB, Neuberg D, Maus MV, Hobbs GS. Antibody and T-cell responses to SARS-CoV-2 vaccination in myeloproliferative neoplasm patients. Leukemia 2022. [PMID: 35217807 DOI: 10.1038/s41375-022-01533-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Sasaki H, Miyata N, Yoshimura Y, Tachikawa N. High titer of antibody against the SARS-CoV-2 spike protein among patients receiving neutralizing antibody cocktail therapy with REGN-COV. Infection 2022. [PMID: 35181864 DOI: 10.1007/s15010-022-01779-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
34 Pitcovski J, Gruzdev N, Abzach A, Katz C, Ben-Adiva R, Brand-Shwartz M, Yadid I, Ratzon-Ashkenazi E, Emquies K, Israeli H, Haviv H, Rapoport I, Bloch I, Shadmon R, Eitan Z, Eliahu D, Hilel T, Laster M, Kremer-Tal S, Byk-Tennenbaum T, Shahar E. Oral subunit SARS-CoV-2 vaccine induces systemic neutralizing IgG, IgA and cellular immune responses and can boost neutralizing antibody responses primed by an injected vaccine. Vaccine 2022;40:1098-107. [PMID: 35078662 DOI: 10.1016/j.vaccine.2022.01.025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
35 Szczepanek J, Skorupa M, Goroncy A, Jarkiewicz-Tretyn J, Wypych A, Sandomierz D, Jarkiewicz-Tretyn A, Dejewska J, Ciechanowska K, Pałgan K, Rajewski P, Tretyn A. Anti-SARS-CoV-2 IgG against the S Protein: A Comparison of BNT162b2, mRNA-1273, ChAdOx1 nCoV-2019 and Ad26.COV2.S Vaccines. Vaccines (Basel) 2022;10:99. [PMID: 35062760 DOI: 10.3390/vaccines10010099] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
36 Jeong S, Lee N, Lee S, Cho E, Hyun J, Park M, Song W, Jung E, Woo H, Seo Y, Park J, Kim H. Seven-Month Analysis of Five SARS-CoV-2 Antibody Assay Results after ChAdOx1 nCoV-19 Vaccination: Significant Decrease in SARS-CoV-2 Antibody Titer. Diagnostics 2022;12:85. [DOI: 10.3390/diagnostics12010085] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Alhazmi A, Alamer E, Abdelwahab S, Khamjan N, Hamami A, Haddad M, Darraj M, Hashem AM, Algaissi A. Community-Based Seroprevalence of SARS-CoV-2 Antibodies following the First Wave of the COVID-19 Pandemic in Jazan Province, Saudi Arabia. Int J Environ Res Public Health 2021;18:12451. [PMID: 34886175 DOI: 10.3390/ijerph182312451] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
38 Ghosh AK, Kaiser M, Molla MMA, Nafisa T, Yeasmin M, Ratul RH, Sharif MM, Akram A, Hosen N, Mamunur R, Amin MR, Islam A, Hoque ME, Landt O, Lytton SD. Molecular and Serological Characterization of the SARS-CoV-2 Delta Variant in Bangladesh in 2021. Viruses 2021;13:2310. [PMID: 34835116 DOI: 10.3390/v13112310] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
39 Bayart JL, Douxfils J, Gillot C, David C, Mullier F, Elsen M, Eucher C, Van Eeckhoudt S, Roy T, Gerin V, Wieers G, Laurent C, Closset M, Dogné JM, Favresse J. Waning of IgG, Total and Neutralizing Antibodies 6 Months Post-Vaccination with BNT162b2 in Healthcare Workers. Vaccines (Basel) 2021;9:1092. [PMID: 34696200 DOI: 10.3390/vaccines9101092] [Cited by in Crossref: 72] [Cited by in F6Publishing: 74] [Article Influence: 72.0] [Reference Citation Analysis]
40 Eyran T, Vaisman-mentesh A, Dror Y, Aizik L, Kigel A, Rosenstein S, Bahar Y, Taussig D, Tur-kaspa R, Kournos T, Markovitch D, Dicker D, Wine Y. The longitudinal kinetics of antibodies in COVID-19 recovered patients over 14 months.. [DOI: 10.1101/2021.09.16.21263693] [Reference Citation Analysis]